April 22, 2021
Business News

Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)


AUSTIN, Texas–()–Entwistle & Cappucci LLP (“Entwistle & Cappucci”) is investigating potential federal securities law violations on behalf of clients that invested in Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) based on: (i) the Company’s contamination of at least 15 million doses of the Johnson & Johnson COVID-19 vaccine; (ii) Emergent’s failure to fix known manufacturing quality issues identified by federal regulators and internal audits; (iii) the Company’s repeated misstatements concerning its quality control, manufacturing process, compliance with applicable regulations and delivery schedule of the Johnson & Johnson vaccine; and (iv) the U.S. Department of Health &…



Click here to view the original article.

Related Posts

You might also like ...

Confluent Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Riassunto: Xsolla acquisisce Slemma, una piattaforma per la visualizzazione e l’analisi avanzata di dati
AMP Robotics Partners with Greenbridge to Increase PET Recovery